MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a voice-based artificial intelligence platform designed to detect drug and alcohol impairment in real time from short speech samples, offering a non-invasive alternative to traditional testing methods. The technology, trained on more than 50 million data points and analyzing over 140 acoustic markers, aims to deliver immediate results through Edge AI kiosks, with initial field testing planned for 2026.
The company's initial commercial focus is on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges. According to MindBio, the global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, creating opportunities to expand the platform into aviation, construction, transportation, law enforcement, call centers and healthcare.
MindBio's proprietary AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy using only the human voice. The company is developing an enterprise platform including Edge-AI kiosks that integrate bespoke hardware and software for detecting drug and alcohol intoxication in various enterprise environments.
The technology addresses the increasing demand for faster, scalable workplace impairment detection. As noted in the full article available at https://ibn.fm/Gw5Fa, the platform could revolutionize safety protocols by providing rapid, non-invasive testing that eliminates the need for breathalyzers, saliva tests or laboratory analysis.
MindBio Therapeutics is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company's latest news and updates are available in its newsroom at https://ibn.fm/MBQIF.
InvestorWire, a specialized communications platform, syndicated this press release. For more information about InvestorWire, visit https://www.InvestorWire.com. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
